Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.57 ^USD	-0.39%		-3.38%	-70.76%

06-24	Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-11	Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	05-09
AbbVie raises annual profit forecast on strong Skyrizi sales	04-26
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-12
Revance Therapeutics Prices $100 Million Public Offering	03-04
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	02-28
Revance Therapeutics, Inc. Announces Executive Changes	02-28
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02-02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02-02
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	12-12
US Consumer group seeks stronger warnings on Botox, similar treatments	12-12
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics	11-08
Top Midday Decliners	19/09/23
Revance Therapeutics Forecasts Impairment Charge of Up to $100 Million Amid Restructuring, Opul Exit; Shares Fall	19/09/23
Insider Sell: Revance Therapeutics	07/09/23
'Barbie Botox' goes viral but doctors inject caution	01/09/23
Revance Therapeutics Says US FDA Approved Daxxify for Involuntary Neck Muscle Contraction	14/08/23
Revance's Botox rival gets FDA approval for painful neck muscle condition	14/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Other languages

Filters